Management of recurrent malignant pleural effusions: an ever-recurring issue?

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Mayo Medical School, Rochester, MN.
² Department of Thoracic Oncology, Pleural Diseases, and Interventional Pulmonology, Hôpital Nord, University of the Mediterranean, Marseille, France. Electronic address: pastoul@ap-hm.fr.

Comment

Fabien Maldonado et al. Chest. 2012 Dec.

. 2012 Dec;142(6):1696.

doi: 10.1378/chest.12-2038.

¹ Division of Pulmonary and Critical Care Medicine, Mayo Medical School, Rochester, MN.
² Department of Thoracic Oncology, Pleural Diseases, and Interventional Pulmonology, Hôpital Nord, University of the Mediterranean, Marseille, France. Electronic address: pastoul@ap-hm.fr.

No abstract available

Comment on

Point: Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes.
Lee P. Lee P. Chest. 2012 Jul;142(1):15-17. doi: 10.1378/chest.12-1085. Chest. 2012. PMID: 22796834 No abstract available.
Counterpoint: should thoracoscopic talc pleurodesis be the first choice management for malignant pleural effusion? No.
Light RW. Light RW. Chest. 2012 Jul;142(1):17-19. doi: 10.1378/chest.12-1087. Chest. 2012. PMID: 22796835 No abstract available.